RxDoctor Payments Data

Shyam Padmanabhan, MD

Cardiovascular Disease · Montgomery, ALNPI 1013224609

Payments from drug & device makers

$9,930in general payments, 2019–2025

Across 179 payments — averaging $55.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$3K
  • Edwards Lifesciences$713
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$271
  • AstraZeneca$225
  • Abbott$224
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$5,62757%
  • Food & beverage$4,08941%
  • Education$2142%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,930 in reported general payments places this provider in the 75th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$123,894
Medicare patients
421
Services billed
1,750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban297$208,593
FarxigaDapagliflozin Propanediol209$160,092
EntrestoSacubitril/Valsartan155$132,982
XareltoRivaroxaban73$57,659
BrilintaTicagrelor99$53,907
Repatha SureclickEvolocumab18$9,741
Metoprolol Succinate359$4,710
Ranolazine ErRanolazine32$2,721
Rosuvastatin Calcium142$2,708
Valsartan66$1,732
Losartan Potassium182$1,725
Prasugrel Hcl36$1,539
Atorvastatin Calcium108$1,483
Isosorbide Mononitrate ErIsosorbide Mononitrate68$1,346
Carvedilol178$1,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$225$213,998308 claims
PfizerEliquis$175$208,593297 claims
NovartisEntresto$189$132,982155 claims
Johnson & JohnsonXarelto$19$57,65973 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →